Benzinga | May 21, 2021 08:21AM EDT

BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer

* BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a first-line treatment of recurrent or metastatic nasopharyngeal cancer, a rare type of head and neck cancer.

* The trial demonstrated a statistically significant improvement (primary endpoint) in progression-free survival compared to chemotherapy alone at the interim analysis, as recommended by an independent data monitoring committee.

* The safety profile of tislelizumab was consistent with its known risks, with no new safety signals identified with the addition of chemotherapy.

* BeiGene plans to discuss these data with health authorities and present data at an upcoming medical conference.

* Price Action: BGNE shares closed at $344.15 on Thursday.